ILKOS THERAPEUTICS

 

 

 

 

 

 

 

ILKOS THERAPEUTICS

 

Specialty Stage Position Board
Venous lower limb ulcers Early Co-Investor Member & Observer
Last update: 28/09/2016

 

Description
ILKOS THERAPEUTICS Inc., a new Québec biotechnology firm tasked with the development of S42909, a compound indicated in the oral treatment of venous lower limb ulcers, a disease that affects 1% to 1.5% of the population, mainly older people. Current treatment, which besides being only moderately effective for complete wound healing and limited to compression bandages and local wound care, is labour intensive, accounting for 1.5% to 2% of the health care budget in countries such as Canada. The new treatment, which seeks to become the first line treatment for venous lower limb ulcers, is a potentially major clinical breakthrough.
The compound has shown promising pharmacological wound healing properties in preclinical trials and was proven to be safe in phase 1 clinical trials on more than 300 healthy volunteers.
The project headed by ILKOS THERAPEUTICS involves demonstrating the efficacy of the compound during a phase 2A multicentre trial conducted in North America and Europe and involving more than 200 patients.

Contact ILKOS THERAPEUTICS Inc.: